Replies to post #167773 on Biotech Values

[jq1234]

Anything but IMO. I like it as well as SRPT now, maybe more from risk/reward standpoint. Also a couple of other relatively undervalued ones in RNA space, TKMR, ARWR - compared to ALNY, ISIS. I think they'll do really well in orphan disease space.